HDAC2 and exocrine pancreatic carcinoma: Improved anti-tumour efficacy has also been reported with the potent HDAC2 inhibitor valproic acid (VPA) that supported Ad-replication in colon carcinoma [41] and oncolytic parvovirus in cervical and pancreatic carcinomas [42].